1081-04-5

Usage

Uses

Used in Organic Synthesis:
5-BROMO-1H-INDAZOLE-3-CARBOXYLIC ACID ETHYL ESTER is used as a building block in organic synthesis for the preparation of various indazole derivatives. Its unique structure and reactivity contribute to the creation of a wide range of compounds with potential applications in different fields.
Used in Pharmaceutical Research:
In Pharmaceutical Research, 5-BROMO-1H-INDAZOLE-3-CARBOXYLIC ACID ETHYL ESTER is utilized as a key intermediate for the development of bioactive compounds. Its role in the synthesis of pharmaceuticals is crucial, as it can lead to the discovery of new drugs with therapeutic potential.
Used in the Preparation of Bioactive Compounds:
5-BROMO-1H-INDAZOLE-3-CARBOXYLIC ACID ETHYL ESTER is employed as a precursor in the synthesis of bioactive compounds, which may possess various biological activities. Its contribution to the development of such compounds is significant, as it can enhance the therapeutic options available in medicine.
Used in the Synthesis of Pharmaceuticals:
In the Pharmaceutical Industry, 5-BROMO-1H-INDAZOLE-3-CARBOXYLIC ACID ETHYL ESTER is used as an intermediate in the synthesis of pharmaceuticals. Its unique properties allow for the creation of new drugs that can address unmet medical needs and improve patient outcomes.

InChI:InChI=1/C10H9BrN2O2/c1-2-15-10(14)9-7-5-6(11)3-4-8(7)12-13-9/h3-5H,2H2,1H3,(H,12,13)

Upstream product

• 4498-67-3 1H-Indazole-3-carboxylic acid 
• 4498-68-4 ethyl 1H-indazole-3-carboxylate 

Downstream Products

• 705264-93-3 (5-bromo-1H-indazol-3-yl)methanol 
• 1448314-55-3 5-bromo-1-(3-methylbenzoyl)-1H-indazole-3-carboxylic acid ethyl ester 
• 1448314-56-4 5-bromo-1-(3-methoxybenzoyl)-1H-indazole-3-carboxylic acid ethyl ester 
• 1428066-10-7 ethyl 5-bromo-1-trityl-1H-indazole-3-carboxylate 

Relevant academic research and scientific papers

METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS

This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.

Optimization of N-benzoylindazole derivatives as inhibitors of human neutrophil elastase

Human neutrophil elastase (HNE) is an important therapeutic target for treatment of pulmonary diseases. Previously, we identified novel N-benzoylindazole derivatives as potent, competitive, and pseudoirreversible HNE inhibitors. Here, we report further development of these inhibitors with improved potency, protease selectivity, and stability compared to our previous leads. Introduction of a variety of substituents at position 5 of the indazole resulted in the potent inhibitor 20f (IC50 ～10 nM) and modifications at position 3 resulted the most potent compound in this series, the 3-CN derivative 5b (IC50 = 7 nM); both derivatives demonstrated good stability and specificity for HNE versus other serine proteases. Molecular docking of selected N-benzoylindazoles into the HNE binding domain suggested that inhibitory activity depended on geometry of the ligand-enzyme complexes. Indeed, the ability of a ligand to form a Michaelis complex and favorable conditions for proton transfer between Hys57, Asp102, and Ser195 both affected activity.

INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS

lndazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole-3- carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.